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Summary
Previously, a single nucleotide polymorphism (SNP), rs9939609, in the FTO gene showed a much 
stronger association with all-cause mortality than expected from its association with body mass 
index (BMI), body fat mass index (FMI) and waist circumference (WC). This finding implies that 
the SNP has strong pleiotropic effects on adiposity and adiposity-independent pathological 
pathways that leads to increased mortality. To investigate this further, we conducted a meta-
analysis of similar data from 34 longitudinal studies including 169,551 adult Caucasians among 
whom 27,100 died during follow-up. Linear regression showed that the minor allele of the FTO 
SNP was associated with greater BMI (n = 169,551; 0.32 kg m−2; 95% CI 0.28–0.32, P < 1 × 
10−32), WC (n = 152,631; 0.76 cm; 0.68–0.84, P < 1 × 10−32) and FMI (n = 48,192; 0.17 kg m−2; 
0.13–0.22, P = 1.0 × 10−13). Cox proportional hazard regression analyses for mortality showed 
that the hazards ratio (HR) for the minor allele of the FTO SNPs was 1.02 (1.00–1.04, P = 0.097), 
but the apparent excess risk was eliminated after adjustment for BMI and WC (HR: 1.00; 0.98–
1.03, P = 0.662) and for FMI (HR: 1.00; 0.96–1.04, P = 0.932). In conclusion, this study does not 
support that the FTO SNP is associated with all-cause mortality independently of the adiposity 
phenotypes.
Keywords
FTO; meta-analysis; mortality; obesity
Introduction
In 2007, genome-wide association studies discovered the first obesity susceptibility locus, 
the ‘fat mass and obesity associated gene’ (FTO) (1,2). A cluster of common single 
nucleotide polymorphisms (SNPs) in the first intron of FTO was identified as those carrying 
the association. Each additional minor A-allele of the rs9939609 SNP in the FTO cluster is 
associated with increased body mass index (BMI) by ~0.40 kg m−2 (1) and an increased risk 
of obesity by 20–30% (1,3). This FTO SNP appears to influence primarily the size of the 
overall fat mass irrespective of the body fat distribution (4). Thus, it is expected that the 
FTO SNP would also be associated with the various health-damaging effects of adiposity. 
Indeed, several analyses using the FTO SNP as instrumental variable of adiposity confirmed 
the causality of the association between adiposity and its detrimental health effects (5–7).
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It would therefore be expected that the FTO SNP is also associated with all-cause mortality. 
In observational studies, an underestimation of the strength of the association between 
adiposity and mortality is suspected because of the likely confounding and reverse causality, 
as indicated in a previous study using the BMI of children as instrumental variable for BMI 
of the parents (8). However, a recent study indicated that the FTO rs9939609 may have a 
much stronger association with all-cause mortality than could plausibly be attributed to such 
biases (9). While the SNP showed the expected association with BMI, it was also associated 
with a doubling of mortality (dominant genetic model), even after adjusting for waist 
circumference (WC), fat mass index (FMI = body fat mass/height2; kg m−2) and BMI at 
younger ages. No distinct associations were found with any of the major causes of death or 
preceding disease incidence that could explain the finding.
On this basis, we speculate that the FTO SNP or some other SNPs tightly linked to it in the 
genomic region may have a major pleiotropic effect influencing pathways implicated in the 
disease processes leading to increased risk of dying independent of body weight regulation. 
To test the hypothesis that the FTO SNP rs9939609 (or any proxy SNP, r2 > 0.80) was 
associated with all-cause mortality, with and without adjustment for BMI, WC and FMI, we 
conducted a meta-analysis based on individual data of Caucasian men and women from 
multiple studies.
Populations and methods
Study selection
We planned a meta-analysis based on novel analyses of longitudinal data. We performed a 
PubMed search using the search terms ‘FTO and obesity’ to identify potential contributing 
studies. Further studies were identified via the network of collaborators who joined the 
meta-analysis and through e-mail within the GIANT (www.broadinstitute.org/collaboration/
giant/index.php/GIANT_consortium) and CHARGE (web.chargeconsortium.com) consortia. 
All studies that included Caucasian populations and that were able to provide baseline data 
on BMI and the FTO SNP genotype, as well as mortality data during the following 
observation time, were considered as eligible (Fig. 1). This resulted in a total of 34 studies 
(Table S1) (10–42). They included 37 cohorts, as in three studies data were analysed 
separately for cohorts established on the basis of follow-up of previously formed cases and 
controls (Health Professionals Follow-up Study (HPFS) (26), Nurses’ Health Studies (NHS) 
(32) and Stockholm Heart Epidemiology program (SHEEP) (39)).
Genotyping
If available, genotyping of the rs9939609 SNP was preferred, but a proxy SNP in high 
linkage disequilibrium with the rs9939609 was used instead in the following studies: EPIC 
Norfolk (rs1121980; r2 = 0.84) (18), EPIC-Potsdam (rs9935401; r2 = 0.98) (19) and Heinz 
Nixdorf Recall Study (rs8050136; r2 = 1) (25). In The Health ABC study (http://
www.grc.nia.nih.gov/branches/leps/healthabc/), the genotype was generated by 1,000 
genome imputation. Only genotype data that met the local quality control criteria, i.e. 
genotyping call rate, concordance in duplicate samples and tests for deviations from Hardy–
Weinberg equilibrium, were used in the analyses.
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Measurement of adiposity phenotype
BMI was calculated for each individual on the basis of measured height and weight 
(exceptions were the use of self-reported data, which have been validated, from The Danish 
1905-Cohort (15), the Danish Diet, Cancer, and Health Cohort (DCH) (16), the NHS (32) 
and the HPFS (26)). Furthermore, 32 of the 37 cohorts included data on WC (10,12,14,16–
35,37–42), which were measured at the same time as height and weight, and 10 studies had 
information on total body fat mass measured by bio-impedance from which FMI was 
calculated (10,14,19,21,23, 24,29,30,42).
Study-specific analyses
All the study-specific analyses were planned to be performed by local analysts according to 
a centrally prepared analysis plan for the covariates and through usage of a hierarchical set 
of Stata scripts (Stata 12.1; StataCorp LP, College Station, TX, USA; 2012), developed by 
the Data Hub at the Institute of Preventive Medicine, Copenhagen, Denmark. The local 
analysts were asked to check the accuracy of their variable assignments and additional 
checks were later performed at the Data Hub. Any detected ambiguities were clarified with 
the respective study investigators before the final meta-analysis stage. All the derived effect 
estimates of the local analyses along with their standard errors were automatically saved in 
corresponding Stata datasets that were returned to the Data Hub. Alternatively, data were 
sent directly and analysed using the same scripts by the Data Hub analyst (LHÄ), which was 
performed for nine studies (12,16,21,23,24,30,31,40,42).
For the main analyses, the effect of the FTO SNP was tested assuming an additive allelic 
effect. However, because in the previous study the effect of the FTO SNP on mortality fitted 
a dominant genetic model (9), this model was also investigated. In order to take into account 
the variation in sex and age, all adiposity phenotypes were subsequently analysed adjusting 
for sex and age using residuals from regressions of the phenotypes on sex, age, age-squared, 
age × sex or age-squared × sex.
Each study tested the association between the FTO geno-type and the adiposity phenotypes 
using linear regression. Further, each study tested for a main effect on mortality of FTO 
genotype, BMI, WC and FMI, respectively. In addition, the associations of the combined 
adiposity pheno-types, (BMI and WC) and (FMI and WC), with mortality were estimated. 
Finally, the association between the FTO genotype and mortality was examined adjusting 
for the single and combined adiposity phenotypes.
Due to the distinct U-shaped association between BMI and mortality (43,44), where the 
increased mortality may not reflect associations with fat mass (45), individuals with BMI < 
20 kg m−2 were excluded from the analyses. However, as the nadir of the U curve has often 
been reported to be around 25 kg m−2 (43,44), there may be a J-shaped relationship between 
BMI above 20 kg m−2 and mortality. Similarly, the association between WC and mortality 
has been reported to be U-shaped (46–48). Studies have shown that WC adjusted for BMI 
and BMI adjusted for WC have monotonic associations with all-cause mortality in opposite 
directions; positive and linear for the WC and decreasing and flattening out for the BMI 
(46,48). Therefore, in the corresponding regression models, both BMI and WC were 
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simultaneously included as linear, quantitative trait variables. FMI has a linear relationship 
with mortality (45,49) and was hence included as a quantitative trait variable in separate 
analyses. In additional analyses, it was also adjusted for WC, which appears to capture the 
effect of the FMI on mortality (49).
The Cox proportional hazards regression model was used for the analyses of mortality and 
the outcome is expressed as hazard ratios (HR) per unit difference of the covariates. The 
participants were followed from date of blood collection for DNA (or from the date of 
anthropometric measurements if that took place later) until death, censoring because of loss 
to follow-up, emigration or end of follow-up. To ensure optimal adjustment for age as a 
major determinant of mortality, we used age as the underlying time scale in the Cox 
regression. This implied entrance of the individual into the estimation of the HR at the age 
when the follow-up began and hence from the age at which the individual was considered at 
risk of dying. Moreover, as the possible pleiotropic effect might be most distinct in the older 
segments of the cohorts (because of the higher mortality), we also performed subgroup 
analyses restricting the minimum age-at-risk to 60, 65 and 70 years, respectively. All Cox 
regression analyses were adjusted for sex and lack of difference in association between the 
two sexes was confirmed. The proportional hazard assumptions were assessed by a test 
based on Schoenfeld residuals (50) using the Stata estat phtest command; only one of 37 
studies (EPIC-Potsdam) showed a significant deviation (P = 0.01).
Meta-analysis
The locally estimated regression coefficients and standard errors were combined by inverse 
variance weighted meta-analyses with random effects (51,52), using the Stata metan 
command (53). In all the meta-analyses, between-study heterogeneity was tested for by the 
Q statistic and quantified by the I2 value; I2 values of <25%, 25–75% and >75% were 
defined as low, moderate and high heterogeneity, respectively (53,54). If the heterogeneity 
turned out to be moderate or high, meta-regression analysis was planned in order to search 
for and adjust for the sources of heterogeneity.
Results
Study characteristics
The 37 participating cohorts provided data on 70,020 men of whom 13,857 died during 
follow-up and 99,531 women of whom 13,243 died during follow-up (Table S1). Regarding 
the mean follow-up time over cohorts, the median length was 9.4 years (range of means 2.9–
20.0 years). Mean baseline age ranged from 38 to 93 years. The minor allele frequency of 
the FTO SNP ranged from 34% to 45%.
Association of FTO with adiposity phenotypes
The association between the FTO SNP and BMI and WC was confirmed; each additional 
minor allele of the FTO SNP was associated with a 0.32 kg m−2 higher BMI and with a 0.76 
cm higher WC (Table 1). In the 10 cohorts with data on FMI, each FTO minor allele was 
associated with a 0.17 kg m−2 higher FMI (Table 1).
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Association of adiposity phenotypes with all-cause mortality
All-cause mortality was positively associated with BMI (HR per unit BMI of 1.02, 95% 
confidence interval [CI]: 1.01–1.03; P = 1.0 × 10−8), but the association went in the opposite 
direction when BMI was concurrently adjusted for WC (HR: 0.97, 95% CI: 0.96–0.98; P = 
4.5 × 10−6) (Table 2). The mortality was positively associated with WC (HR: 1.01, 95% CI: 
1.01–1.02; P = 5.6 × 10−24), also when concurrently adjusted for BMI (HR: 1.02, 95% CI: 
1.02– 1.03; P = 8.8 × 10−18) (Table 2). Mortality was positively associated with FMI alone 
(HR: 1.05 (95% CI: 1.02–1.08; P = 0.003), but negatively associated when adjusted for WC 
(HR: 0.97, 95% CI: 0.95–0.99; P = 0.009) (Table 2).
Associations of FTO with all-cause mortality
FTO was associated (albeit non-significantly) with all-cause mortality with a HR of 1.02 
(95% CI: 1.00–1.04; P = 0.097) per minor allele. Adjustment for BMI and WC attenuated 
the estimate to a HR of 1.00 (95% CI: 0.98–1.03; P = 0.662) (Fig. 3).
In the subset of 10 studies including 48,192 individuals with FMI data (6,436 deaths), each 
minor FTO allele was associated with mortality with a HR of 1.01 (95% CI: 0.96–1.06; P = 
0.731) and a HR of 1.00 (95% CI: 0.96– 1.04; P = 0.932) when adjusted for FMI (Fig. 4).
The analyses assuming a dominant genetic model showed no association between FTO and 
mortality (HR of 1.00, 95% CI: 0.98–1.03; P = 0.901). The age-restricted subgroup analyses 
(observations left-truncated with delayed entry at 60, 65 and 70 years, respectively) and the 
sex-specific analyses showed results consistent with the non-censored analyses (Tables S2 & 
S3).
The heterogeneity in all meta-analyses was very low, so there was no reason to conduct a 
comprehensive meta-regression analysis. The possible modification of the FTO–mortality 
association by mean age at events in each cohort was addressed by a meta-regression 
analysis, which did not show a significant relationship.
Discussion
In this meta-analysis, combining data of up to 169,551 adults of whom 27,100 died during 
follow-up, we found a very modest and statistically insignificant effect of the adiposity-
associated FTO SNPs on all-cause mortality. When assuming an additive genetic effect, 
each minor allele increased mortality by ~2% with CIs ranging from ~0% to ~4% (Fig. 2). 
When adjusting for the adiposity phenotypes, there was virtually no association between the 
FTO SNPs and all-cause mortality.
Our results do not support the findings from the previous study, which reported a 
statistically significant very strong positive association between the FTO rs9939609 SNP 
and all-cause mortality (9). In the previous study, FTO minor allele carriers had almost 
twice the mortality rate of the homozygous carriers of the major allele when analysed in a 
dominant genetic effect model (9). The results from the present meta-analysis provide 
evidence that if FTO has an effect on mortality that is not attributable to its association with 
the adiposity phenotypes, it is – almost without doubt – much smaller than that found in the 
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previous study (as indicated by the CI). Hence, the results of the previous study are likely to 
be spurious, possibly reflecting random sampling errors irrespective of its statistical strength 
and otherwise consistent associations between the FTO SNP and the adiposity phenotypes 
and their associations with all-cause mortality (4,9). On the other hand, several previous 
studies have investigated the association between FTO and cardiovascular disease and the 
results were recently pooled in a meta-analysis (55). The overall conclusion was that FTO 
was associated with an increased cardiovascular risk independent of its association with 
BMI (55). Whether FTO has adiposity-independent effects on mortality from specific causes 
remains an important challenge for future research to elucidate.
The association between the FTO SNP and mortality was robust as judged from the narrow 
CIs and the low heterogeneity. Consistent results were also found when restricting the time-
at-risk to older ages (above 60, 65 and 70 years, respectively) and to each sex, indicating no 
effect modifications by age and sex. When assuming a dominant effect for the minor allele, 
no association was found between the FTO SNP and mortality. Moreover, as addressed in 
the following, the associations between the FTO SNP and the adiposity phenotypes as well 
as the associations between the adiposity phenotypes and all-cause mortality were generally 
as expected from previous studies.
We estimated an effect size for BMI per minor allele of FTO to 0.32 kg m−2, which is 
similar to the findings in other large-scale studies in Caucasian adults, where effect sizes 
ranging between 0.26 and 0.39 kg m−2 have been reported (1,56–59). The corresponding 
effect size for WC in the present meta-analysis was 0.76 cm per additional minor allele, 
which is within the range of 0.73–1.00 cm per additional minor allele previously reported in 
large-scale studies in Caucasian adults (1,57,60).
Our linear estimates of associations between BMI and mortality and between WC and 
mortality are probably biased because of the U- or J-shaped associations (43–46,48,49), but 
the other estimated associations shown in Table 2 are likely to reflect the expected 
monotonic, approximate linear associations (45,46,48,49). Thus, previous studies suggest 
that WC has a strong positive relation to mortality when adjusted for BMI, whereas BMI 
adjusted for WC is inversely associated with mortality (46–48). In agreement with these 
relationships, a study found a direct association between fat mass and mortality and an 
inverse association between lean mass and mortality (45). Further, when adjusting fat mass 
for WC, the positive association with mortality was eliminated, whereas adjustment of lean 
mass for WC did not alter the association with mortality (49).
As reported by others studying the relation between the FTO SNPs and the health-damaging 
effects of adiposity (5–7), the present study offers an opportunity to interpret the association 
of the adiposity phenotypes with all-cause mortality in the conceptual framework of so-
called Mendelian randomization analysis by using the FTO SNP as an instrumental variable 
(61). A key requirement of these analyses is that the instrumental variable, here the alleles of 
the SNP, is associated with the factor to be investigated, here mortality, only through the 
investigated cause, here the adiposity phenotypes, i.e. there must be no pleiotropic effects. 
The present results support this assumption for the FTO SNP. Such analysis provides a 
calculation of the association of the adiposity phenotypes with mortality that is presumed to 
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be unbiased by confounding or reverse causality and may hence be interpreted as evidence 
for a causal relation (61). For both BMI and FMI, the causal calculation for mortality is a 
HR of 1.05 per kg m−2. This is greater than the observed mortality for BMI (HR of 1.02), 
but equal to that observed for FMI. The lower mortality observed for BMI than calculated 
from the instrumental variable analysis may reflect confounding and reverse causality, 
possibly inducing the inverse relation between the lean body mass component of BMI and 
mortality (45). The equality of the observed and calculated HR for FMI suggests that the 
observed association between FMI and mortality is probably unbiased and may reflect a 
causal relation.
The construction of the present study does not allow us to conduct a proper in-depth 
Mendelian randomization analysis (61). In spite of the size of the study, it was not originally 
set up to address such analysis and there remains considerable statistical uncertainty of the 
components used for the calculations. Furthermore, the inference would be considerably 
improved by various measures such as inclusion of adiposity-associated SNPs in other 
genomic regions, integration of the different measures of body composition and shape, 
calculation of the associations of the adiposity phenotypes with mortality under proper 
control of the well-known confounding factors (e.g. smoking), analyses taking into account 
non-linear relations between the adiposity phenotypes and mortality and subdivision of the 
mortality by age at death and by major causes of death.
The key strength of the present study is that it is strictly hypothesis-driven and designed for 
and capable of testing the proposed hypothesis. The meta-analysis was based on analysis of 
original individual participant data according to a standardized plan in all eligible cohorts. 
This analytical standardization across studies minimized study heterogeneity and the usage 
of all identified data minimized bias related to study selection, which might otherwise have 
caused serious publication bias because of the difficulty in publishing null results. However, 
as the study was conducted among Caucasians only, it is difficult to generalize the results to 
other ethnic groups.
We conclude that the FTO SNP is not associated with all-cause mortality independently of 
the adiposity phenotypes.
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Figure 1. 
Study design of the FTO–mortality meta-analysis. Eligible studies were identified by a 
literature search, as well as through network of the collaborators and calls in the 
international consortia GIANT and CHARGE (labelled ‘other sources’ in the figure). Of all 
studies that were invited, 34 studies of adults (n = 169,551) participated in the meta-analysis. 
Standardized Stata scripts were sent to each of the studies, 25 studies analysed data locally 
and nine studies were analysed centrally at the coordinating Data Hub. All the local 
estimates were meta-analysed.
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Figure 2. 
Forest plot of the effect of FTO rs9939609 on all-cause mortality in a random effects meta-
analysis of 169,551 Caucasian adults sorted by number of deaths. The studies are sorted by 
decreasing sample size (the largest at the top). Details of the studies are given in Table S1. 
The overall estimate equalled a HR of 1.016 (0.997–1.035), P = 0.097.
95% CI, 95% confidence intervals; Deaths, number of deaths; HR, estimated hazard ratio of 
all-cause mortality per minor allele of the rs9939609 or a proxy (r2 > 0.8); n, number of 
individuals.
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Figure 3. 
Forest plot of the effect of FTO rs9939609 on all-cause mortality adjusted for body mass 
index and waist circumference in a random effects meta-analysis of 152,631 Caucasian 
adults sorted by number of deaths. The studies are sorted by decreasing sample size (the 
largest at the top). Details of the studies are given in Table S1. The overall estimate equalled 
a HR 1.004 (0.983–1.027), P = 0.662.
95% CI, 95% confidence intervals; Deaths, number of deaths; HR, estimated hazard ratio of 
all-cause mortality per minor allele of the rs9939609 or a proxy (r2 > 0.8); n, number of 
individuals.
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Figure 4. 
Forest plot of the effect of FTO rs9939609 on all-cause mortality adjusted for fat mass index 
in a random effects meta-analysis of 48,192 Caucasian adults sorted by number of deaths. 
The studies are sorted by decreasing sample size (the largest at the top). Details of the 
studies are given in Table S1. The overall estimate equalled a HR 0.998 (0.956–1.042), P = 
0.932.
95% CI, 95% confidence intervals; Deaths, number of deaths; HR, estimated hazard ratio of 
all-cause mortality per minor allele of the rs9939609 or a proxy (r2 > 0.8); n, number of 
individuals.
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Table 1
Association of the minor (A) allele of the rs9939609 SNP in FTO with BMI, WC and FMI, respectively, in a 
random effects meta-analysis of Caucasian adults
Phenotype n β (95% CI) P-value
BMI (kg m−2) 169,551 0.32 (0.28-0.32) <1 × 10−32
WC (cm) 152,631 0.76 (0.68-0.84) <1 × 10−32
FMI (kg m−2) 48,192 0.17 (0.13-0.22) 1.0 × 10−13
β, estimated difference in phenotype per minor allele of the rs9939609 or a proxy (r2 > 0.8); BMI, body mass index; CI, confidence interval; FMI, 
fat mass index; n, number of individuals; SNP, single nucleotide polymorphism; WC, waist circumference.
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Table 2
Association of BMI, WC and FMI with all-cause mortality in a random effects meta-analysis of Caucasian 
adults
Phenotype n Deaths HR (95% CI) P-value
BMI (kg m−2)a 169,551 27,100 1.02 (1.01-1.03) 1.0 × 10−8
BMI (kg m−2)IWC 152,631 22,506 0.97 (0.96-0.98) 4.5 × 10−6
WC (cm)b 152,631 22,506 1.01 (1.01-1.02) 5.6 × 10−24
WC (cm)IBMI 152,631 22,506 1.02 (1.02-1.03) 8.8 × 10−18
FMI (kg m−2) 48,192 6,436 1.05 (1.02-1.08) 0.003
FMI (kg m−2)IWC 48,167 6,433 0.97 (0.95-0.99) 0.009
BMI, body mass index; CI, confidence interval; FMI, fat mass index; HR, estimated hazard ratio of all-cause mortality per unit of the phenotype; n, 
number of individuals; WC, waist circumference; I, means adjusted for; e.g. BMI (kg m−2)IWC is BMI adjusted for waist circumference.
a
Due to the assumption of linearity of the BMI-mortality association for BMI ≥ 20 kg m−2, the association between high levels of BMI and 
mortality is potentially underestimated.
b
Due to the assumption of linearity of the WC-mortality association, the association between high levels of WC and mortality is potentially 
underestimated.
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